



## FOLDAX APPOINTS GREGORY D. CASCIARO AS CHIEF EXECUTIVE OFFICER

**SALT LAKE CITY, Utah – October 18, 2022** – Foldax®, Inc. today announced that medtech veteran Gregory D. Casciaro has been named Chief Executive Officer of the company, effective yesterday. In his more than 30 years in the medical technology arena, Mr. Casciaro has developed a track record of success leading and growing both private and public companies, from clinical through commercial phases, and from fundraising through acquisitions. He also brings strong strategic insights to the company as an experienced board member and advisor.

As President and CEO of Access Closure, General Surgical Innovations, Orquest, and XTNT, he led all four companies to successful exits via acquisitions by, respectively, Cardinal Health, U.S. Surgical (now Medtronic), Johnson and Johnson (J&J), and Biosensors International. His experience also includes serving as President and CEO for Cardiac Dimensions, and in executive and management roles at Guidant's Devices for Vascular Intervention division and North American Instrument Corp. Currently, he serves on the board of directors for Colospan, Cytokind, Tulavi Therapeutics and KL Acquisition Corp., and has held board roles with AngioDynamics, Apama Medical, Dexter Surgical, Kerberos Proximal Solutions, and QT Vascular. He has also served as strategic advisor for RenalPro.

"Greg has enjoyed tremendous success leading and growing medtech companies, many of them in the cardiovascular space. His strategic guidance and leadership helped many of them navigate sometimes complex paths to market and resulted in successful acquisitions by industry leaders," said Ken Charhut, Executive Chairman of the Board for Foldax. "We are delighted that Greg is joining us as we execute on our mission to bring a transformational heart valve platform to clinics and patients around the world."

"Foldax has a groundbreaking technology with the potential to solve perennial problems that have plagued heart valves for decades, and I am excited to lead the team working to make this promise a reality," said Mr. Casciaro. "Reimagining how heart valves are designed and manufactured is a unique and special opportunity that I believe can benefit from my wealth of experiences."

### **About [Foldax](#)**

Headquartered in Salt Lake City, Utah, Foldax is reinventing every aspect of the heart valve – from material to design to manufacturing – to develop surgical and transcatheter valves designed to last a lifetime addressing historical tradeoffs.

Foldax investors include Angel Physicians Fund, Biostar Capital, Caltech, Glenview Capital, Kairos Ventures, Memorial Care Innovation Fund and Sayan Bioventures.

###

**MEDIA CONTACT:**

Michelle McAdam, Chronic Communications, Inc.

[michelle@chronic-comm.com](mailto:michelle@chronic-comm.com)

(310) 902-1274